Table 2.
Control | Chronic MS | OV+MS | OV | |
---|---|---|---|---|
EDL mass (mg per g M b) | 0.57 ± 0.05a | 0.59 ± 0.06a | 0.68 ± 0.06b | 0.67 ± 0.03b |
Bilateral EDL mass hypertrophy | 1.02 ± 0.09a | 1.06 ± 0.010a | 1.19 ± 0.07b | 1.19 ± 0.06b |
Anatomical capillary density (mm2) | 617 ± 61a | 556 ± 63a | 813 ± 114b | 836 ± 131b |
Perfused capillary density (mm2) | 564 ± 107a | 420 ± 95b | 512 ± 48ab | 728 ± 165c |
Anatomical capillary: muscle fibre | 1.47 ± 0.30ab | 1.29 ± 0.13a | 1.66 ± 0.19b | 1.63 ±0.22b |
Perfused capillary: muscle fibre | 1.25 ± 0.29ab | 0.96 ± 0.19a | 0.92 ± 0.18a | 1.42 ± 0.31b |
Anatomical CDA (µm2) | 1399 ± 156a | 1841 ± 204b | 1414 ± 158a | 1337 ± 155a |
Perfused CDA (µm2) | 1854 ± 397a | 2506 ± 765a | 2274 ± 519a | 1759 ± 521a |
Anatomical logrSD | 0.107 ± 0.008a | 0.096 ± 0.010a | 0.100 ± 0.012a | 0.104 ± 0.008a |
Perfused logrSD | 0.127 ±0.016a | 0.109 ± 0.008a | 0.112 ± 0.019a | 0.112 ± 0.014a |
Type I (%) | 3.8 ± 2.1a | 3.9 ± 2.2a | 3.3 ± 1.8a | 3.5 ± 2.4a |
Type 1 FCSA (µm2) | 922 ± 217a | 1008 ± 138a | 1042 ± 180a | 1010 ± 173a |
Type IIa (%) | 21.4 ± 5.0a | 19.9 ± 5.4a | 21.5 ± 4.2a | 23.2 ± 6.2a |
Type IIa FCSA (µm2) | 933 ± 99a | 1012 ± 133ab | 1169 ± 120b | 1113 ± 120b |
Type IIb/IIx (%) | 74.8 ± 6.9a | 76.2 ± 7.3a | 75.1 ± 4.2a | 73.3 ± 8.5a |
Type IIb/IIx FCSA (µm2) | 1644 ± 189a | 2085 ± 310b | 2269 ± 182b | 2121 ± 223b |
Abbreviations: CDA, capillary domain area; FCSA, fibre cross‐sectional area. Superscript letters denote statistical significance (P ≤ 0.05) as assessed by Tukey post hoc tests.